Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03495921
Title Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gradalis, Inc.
Indications

Ewing sarcoma

Therapies

FANG vaccine + Irinotecan + Temozolomide

Irinotecan + Temozolomide

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.